Lilly applies for Alzheimer's drug's US approval after trial success | Business

Eli Lilly & Co. said it applied for full U.S. approval of its Alzheimer’s disease drug that’s expected to compete with Eisai Co.’s Leqembi as the U.S. drugmaker revealed details

Related Keywords

California ,United States ,Amsterdam ,Noord Holland ,Netherlands ,San Francisco ,New York ,Eric Widera ,Eisai Leqembi ,Maria Carrillo ,David Knopman ,Alzheimer Association International Conference ,Biogen Inc ,Alzheimer Association ,Drug Administration ,University Of California ,Eli Lilly Co ,Eisai Co ,Eli Lilly ,Association International Conference ,Mayo Clinic ,Business And Commerce ,Government Regulatory Actions ,Business Regulation ,Ealth And Wellness ,Drug And Device Approval Process ,Edical Conditions And Diseases ,Drug Testing And Approval Process ,Egulatory Drug Approval ,Edicinal Drugs ,Emerging Treatments ,Medical And Pharmaceutical Regulation ,Reatments And Therapies ,Rading Impact Ice Codes Important Corporate Events ,Ife And Society ,Aging And The Elderly ,Olitics And Government ,Overnment Agencies Us ,Food And Drug Administration ,Department Of Health And Human Services ,Government Regulation ,Pharmaceuticals ,Manufacturing ,Manufactured Drugs ,North America ,Western Europe ,Americas ,Europe ,The Netherlands ,New York City ,